The combination of gemcitabine and carboplatin as first‐line treatment in patients with advanced urothelial carcinoma
Open Access
Abstract
BACKGROUND: The toxicity of platinum‐based combinations represents a common problem for patients with advanced urothelial carcinoma. The authors previously reported encouraging efficacy for the combination of carboplatin and gemcitabine in patients considered to be unfit for cisplatin‐based treatment. The objective of the current multicenter Phase II study was to evaluate the safety and efficacy of the combination of gemcitabine and carboplatin as first‐line treatment in unselected patients with advanced urothelial carcinoma.METHODS: Patients with previously untreated, bidimensionally measurable, inoperable or metastatic urothelial carcinoma were treated with carboplatin, area under the concentration curve of 5 (Day 1) and gemcitabine at a dose of 1000 mg/m2 (Days 1 and 8), every 21 days for a total of 6 cycles.RESULTS: Sixty patients (49 men and 11 women, with a median age of 69 yrs) were enrolled in the current study. Intent‐to‐treat analysis demonstrated an objective response rate (ORR) of 38.4% (95% confidence interval [95% CI], 26–51.8%) (11.7% complete responses and 26.7% partial responses). The median time to disease progression was 7.6 months (95% CI, 4.5–10.7 mos) and the median overall survival was 16.3 months (95% CI, 12–20.6 mos). The median survival was comparable to that reported for the combination of methotrexate, vinblastine, doxorubicin, and cisplatin (M‐VAC) according to the Memorial Sloan‐Kettering Cancer Center prognostic model for patients with similar baseline prognostic features. Grade 3 or 4 toxicity (according to the National Cancer Institute Common Toxicity Criteria [version 2.0]) included anemia (18%), thrombocytopenia (23%), and neutropenia (52%), with 7 episodes of febrile neutropenia (11%) reported. Nonhematologic toxicity was rare. One toxic death occurred during the study.CONCLUSIONS: The combination of gemcitabine and carboplatin appears to have considerable activity as the first‐line treatment of unselected patients with advanced urothelial carcinoma with manageable toxicity, and deserves further evaluation in this setting. Cancer 2006. © 2005 American Cancer Society.Keywords
This publication has 31 references indexed in Scilit:
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapyAnnals of Oncology, 2005
- Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urotheliumCancer, 2004
- Docetaxel and Cisplatin With Granulocyte Colony-Stimulating Factor (G-CSF) Versus MVAC With G-CSF in Advanced Urothelial Carcinoma: A Multicenter, Randomized, Phase III Study From the Hellenic Cooperative Oncology GroupJournal of Clinical Oncology, 2004
- Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tractCancer, 2003
- Overview of bladder cancer trials in the European Organization for Research and TreatmentCancer, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Carboplatin-based chemotherapy for bladder cancerCancer Treatment Reviews, 1993
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958